关于阿德福韦酯与拉米夫定治疗乙型肝炎肝硬化的疗效研究

Study on the effect of adefovir and lamivudine in treatment of hepatitis B cirrhosis

目的分析拉米夫定与阿德福韦酯治疗乙型肝炎肝硬化患者的临床疗效。方法患者入院治疗后均给予对症治疗、护肝及保肝等常规治疗,采用拉米夫定治疗A组患者,剂量为100 mg/d;采用阿德福韦酯治疗B组患者,剂量为10mg/d;联合应用阿德福韦酯与拉米夫定治疗C组患者,拉米夫定剂量为100 mg/d,阿德福韦酯为10mg/d。结果 C组HBV DNA水平与A组及B组相比存在显著性差异(P<0.05);C组HBV DNA的转阴率也明显高于A组及B组,且存在显著性差异(P<0.05)。C组的肝功能明显优于A组及B组(P<0.05)。结论联合阿德福韦酯与拉米夫定治疗肝硬化的临床疗效显著,可推广应用。

Objective To analyze the clinical efficacy in patients with lamivudine and adefovir dipivoxil in the treatment of hepatitis B cirrhosis. Patients were given symptomatic treatment, liver and liver and other conventional treatment. Methods In patients after treatment, A group were treated with lamivudine treatment, a dose of 100mg/d; with adefovir dipivoxil in the treatment of patients in the B group, the dose of 10mg/d; the application of adefovir and lamivudine in the treatment of C patients with lamivudine, adefovir dose of 100mg/d, 10mg/d. Results In group C, HBV and DNA level of A group and B group compared to the exis-tence of significant differences （P〈0.05）; group C HBV DNA negative rate were significantly higher than those in A group and B group, and the difference was significant （P〈0.05）. C group of liver function was better than that in A group and B group （P〈0.05）. Conclusion The curative effect of combined with adefovir and lamivudine in treatment of liver cirrhosis was significantly, can be applied.